上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
12期
10-12,25
,共4页
韩晶%丁涵之%全红%严伟国
韓晶%丁涵之%全紅%嚴偉國
한정%정함지%전홍%엄위국
乳腺癌%分子检测%毒副反应%敏感性%化疗
乳腺癌%分子檢測%毒副反應%敏感性%化療
유선암%분자검측%독부반응%민감성%화료
breast cancer%molecular detection%toxicity%sensitivity%chemotherapy
目的:分析根据分子检测技术选择的化疗药物的毒副反应及有效性。方法:选择246例乳腺癌术后患者分为检测组150例和常规组96例。检测组采用分子预测法对常用化疗药物进行分子检测,并根据结果选择敏感性高及毒副作用低的药物进行化疗;常规组采用常规化疗。结果:TEC方案化疗的粒细胞减少以及呕吐发生率在检测组明显低于常规组(P<0.05),CEF-T/EC-T(H)方案化疗的粒细胞减少发生率在检测组明显低于常规组(P<0.05)。结论:根据分子检测选择的化疗方案的毒副反应明显低于常规化疗,但药物敏感性是否带来有效性的提高而产生生存获益,尚需更长时间的随访。
目的:分析根據分子檢測技術選擇的化療藥物的毒副反應及有效性。方法:選擇246例乳腺癌術後患者分為檢測組150例和常規組96例。檢測組採用分子預測法對常用化療藥物進行分子檢測,併根據結果選擇敏感性高及毒副作用低的藥物進行化療;常規組採用常規化療。結果:TEC方案化療的粒細胞減少以及嘔吐髮生率在檢測組明顯低于常規組(P<0.05),CEF-T/EC-T(H)方案化療的粒細胞減少髮生率在檢測組明顯低于常規組(P<0.05)。結論:根據分子檢測選擇的化療方案的毒副反應明顯低于常規化療,但藥物敏感性是否帶來有效性的提高而產生生存穫益,尚需更長時間的隨訪。
목적:분석근거분자검측기술선택적화료약물적독부반응급유효성。방법:선택246례유선암술후환자분위검측조150례화상규조96례。검측조채용분자예측법대상용화료약물진행분자검측,병근거결과선택민감성고급독부작용저적약물진행화료;상규조채용상규화료。결과:TEC방안화료적립세포감소이급구토발생솔재검측조명현저우상규조(P<0.05),CEF-T/EC-T(H)방안화료적립세포감소발생솔재검측조명현저우상규조(P<0.05)。결론:근거분자검측선택적화료방안적독부반응명현저우상규화료,단약물민감성시부대래유효성적제고이산생생존획익,상수경장시간적수방。
Objective:To analyze the toxicity and effecacy of chemotherapy based on molecular detection techniques. Methods: Two hundred and forty-six patients with breast cancer were enrolled in the study and divided into a study group (n=150) and a control group(n=96). Molecular detection for selection of chemotherapy drugs was carried out. The patients in the study group were treated with high sensitivity and low toxicity chemotherapy drugs based on molecular detection results. Meanwhile , patients in the control group were treated with conventional chemotherapy. Results: For patients with TEC chemotherapy, both neutropenia and vomiting were signiifcantly lower in the study group than in the control group(P<0.05). For patients with CEF-T/EC-T(H) chemotherapy, neutropenia was also signiifcantly lower in the study group than in the control group(P<0.05).Conclusion:The toxicity of chemotherapy based on molecular detection was signiifcantly lower in the study group than in the control group. However, long follow-up is needed to determine whether the sensitivity of chemotherapy drugs will improve therapeutic effect or survival beneift.